Abstract:

Abstract:Objective  To study the chemosensitivity difference of diffferent genotypes of CD44 at  rs4756195 to anthracyclines-based chemotherapy in breast cancer patients and clarify the association between CD44 polymorphisms and their chemosens
itivities to anthracyclines-based chemotherapy in breast cancer.Methods The polymorphisms of CD44 at rs4756195 in a total
of 120 patients with breast cancer treated with anthracycline-based neoadjuvant chemotherapy were detected by Sequenom MassArray iPLEX GOLD System. After 2 to 3 cycles of chemotherapy,the differences in the overall response and the rate of pathological complete remission (pCR) were analyzed with Logistic regression analysis.Results The overall response of the patients with breast cancer who carried with GG genotype had no significant difference compared with those carried with AA and AG genotypes (73.6%   vs  69.0%，χ²=0.240，P=0.625),and the rate of pCR in breast cancer patients carried with AA and AG genotypes was higher than those carried with GG genotype (55.2%   vs  16.5%，χ²=17.181，P=0.000；OR=13.935，95%CI=4.359　－44.541，P=0.000).Conclusion CD44 rs4756195 polymorphisms are closely associated with the response to anthracyclines-based chemotherapy in breast cancer patients,and the patients with breast cancer who carried with A allelotype have the higher rate of pCR.CD44 rs4756195 polymorphisms may be used as one of the indicators to evaluate the hemotherapeutic response of the patients with breast cancer.

Key words: breast tumor, CD44 gene, gene polymorphism, chemosensitivity